Method Profile
Primary human skin equivalents with different CD4+ and CD8+ T-cell combinations support tissue and cytokine measurements during anti-inflammatory drug testing.
Investigation of immune-subset and donor contributions to psoriasis-associated pharmacological responses.
Healthy-donor keratinocytes/fibroblasts in a full-thickness tissue combined with polarized Th1/Th17, Tc1/Tc17 or mixed T-cell populations.
Three-day immune co-culture with 2.5 μM apremilast introduced at T-cell integration; secreted mediators normalized to matched untreated compositions.
Human tissues
Stratified epidermis and fibroblast-populated dermal support from healthy donor tissue.
Immune component
Healthy-volunteer CD4+ and CD8+ subsets polarized into defined type 1/type 17 combinations.
Measurements
Cytokine secretion, histology, differentiation markers and antimicrobial proteins.
Retain donor-level patterns and distinguish independent donor experiments from within-experiment technical triplicates.
Compare subset composition with and without apremilast, alongside transferred T-cell-free controls and a non-transferred handling reference.
Four independent experiments using different skin/T-cell donors, with technical triplicates in each condition.
Matched untreated cell combinations and T-cell-free skin equivalents.
CD4+ cultures showed cytokine-suppression trends in most donors without pooled statistical significance; CD8+ cultures were largely unresponsive. IL-6 increased across T-cell-containing donor cultures.
Full-thickness human skin equivalents developed psoriasis-associated features after addition of defined CD4+ or CD8+ T-cell subsets. Apremilast responses differed by subset and donor, with cytokine-suppression trends in CD4+ cultures failing to reach statistical significance.
